IPO
A summary of IPOs from companies in the biotech and pharma world since February 1, 2019.
Gossamer Bio has been the poster child for biotech companies struggling with IPO launches during the shutdown.
BioArctic AB to publish the company’s Full Year Report for the period January – December 2018 on Thursday, February 14, 2019 at 08:00 a.m. CET.
The government shutdown threw a wrench into several biotech company’s plans for initial public offerings (IPOs). Although the government is only guaranteed to stay open until February 15, several biotechs are working to get their IPOs launched in that window. Here’s a look.
Suven Life Sciences Limited announced its Un-audited financial results for the quarter ended 31st December 2018.
Cash position of €207.2 million as of December 31, 2018, compared to €273.8 million as of December 31, 2017
Immunicum AB announced that Carlos de Sousa, CEO of Immunicum, and other members of the management team will present at upcoming investor conferences in February.
You have to give San Diego-based Gossamer Bio credit for the way it’s adapted its plans for an initial public offering (IPO) to deal with the government shutdown.
The subscription price for warrant TO1 in Promore Pharma AB has been determined according to the terms and conditions forthe warrants to 23.30 SEK per share.
Immunicum AB has, as previously announced, implemented a share issue with preferential rights for the Company’s existing shareholders.
PRESS RELEASES